IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition
This study has been completed.
Sponsor:
Watson Pharmaceuticals
Information provided by (Responsible Party):
Watson Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00224016
First received: September 13, 2005
Last updated: February 7, 2012
Last verified: February 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This study will evaluate the safety and effectiveness of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in children who have a neurological condition (e.g. spina bifida) that contributes to their overactive bladder.
| Condition | Intervention | Phase |
|---|---|---|
| Detrusor Hyperreflexia | Drug: Oxybutynin | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | A Multi-Center, Open-Label (OL), Active-Controlled, Dose-Titration Study Evaluating the Safety, Efficacy and PK of Oxybutynin Transdermal Systems in the Treatment of Detrusor Overactivity in Pediatric Patients |
Resource links provided by NLM:
Further study details as provided by Watson Pharmaceuticals:
Primary Outcome Measures:
- Average Catheterization Urine Volume [ Time Frame: 14 weeks ]Change from baseline in average volume of urine collected by catheterization
Secondary Outcome Measures:
- Catheterizations Without Leakage [ Time Frame: 14 weeks ]Percentage of catherizations without leakage
- Urine Volume After First Awakening [ Time Frame: 14 weeks ]Change from baseline in average volume of urine collected after first morning awakening
| Enrollment: | 57 |
| Study Start Date: | December 2004 |
| Study Completion Date: | September 2008 |
| Primary Completion Date: | April 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Oxybutynin Transdermal System
Oxybutynin Transdermal System 1.3 mg/day, 2.6 mg/day, or 3.9 mg/day
|
Drug: Oxybutynin
1.3, 2.6, 3.9 mg/day transdermal
Other Name: Oxytrol
|
|
Active Comparator: Oral oxybutynin
5 to 15 mg/day immediate release or extended release tablets, or syrup
|
Drug: Oxybutynin
5 to 15 mg/day immediate release or extended release tablets, or syrup
Other Name: Ditropan, Ditropan XL, Oxybutynin
|
Detailed Description:
This study will use a multicenter, randomized, open-label, active-controlled, dose-titration, parallel group design, in approximately pediatric patients with detrusor overactivity associated with a neurological condition.
Eligibility| Ages Eligible for Study: | 6 Years to 15 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Pediatric patient with a diagnosis of detrusor overactivity associated with a neurological condition;
- Use clean intermittent catheterization
- On stable dose of oral oxybutynin before participation
Exclusion Criteria:
- Have one or more treatable conditions, other than neurogenic bladder dysfunction, that may cause urinary incontinence or urgency
- Have any medical condition that precludes their participation in the study or may confound the outcome of the study
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00224016
Show 23 Study Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00224016
Show 23 Study Locations
Sponsors and Collaborators
Watson Pharmaceuticals
Investigators
| Study Chair: | Gary Hoel, RPh, PhD | Watson Laboratories, Inc. |
More Information
Publications:
| Responsible Party: | Watson Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00224016 History of Changes |
| Other Study ID Numbers: |
O03010 |
| Study First Received: | September 13, 2005 |
| Results First Received: | November 13, 2009 |
| Last Updated: | February 7, 2012 |
Additional relevant MeSH terms:
|
Reflex, Abnormal Neurologic Manifestations Nervous System Diseases Signs and Symptoms Oxybutynin Mandelic Acids Parasympatholytics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Urological Agents Anti-Infective Agents, Urinary Anti-Infective Agents Renal Agents |
ClinicalTrials.gov processed this record on September 21, 2017